Mehrdad Mobasher Net Worth

Mehrdad Mobasher biography

Dr. Mehrdad Mobasher M.D., M.P.H. serves as Vice President, Chief Medical Officer of the Company. Prior to joining the Company, Dr. Mobasher was employed by Genentech/Roche from August 2010 to January 2019, most recently as a Group Medical Director and Development Lead for venetoclax. He has also served as an adjunct clinical faculty member in the Division of Medical Oncology at Stanford University from September 2011 to September 2012. Dr. Mobasher received an M.D. from Tehran University of Medical Sciences, and an M.P.H. in general epidemiology from the School of Public Health at the University of Michigan. He completed an internship and residency in internal medicine at the University of California, Irvine, and post-doctoral fellowships in hematology and medical oncology at Stanford University.

What is the salary of Mehrdad Mobasher?

As the Vice President and Chief Medical Officer of Corvus Pharmaceuticals Inc, the total compensation of Mehrdad Mobasher at Corvus Pharmaceuticals Inc is $1,357,160. There are 1 executives at Corvus Pharmaceuticals Inc getting paid more, with Daniel Hunt having the highest compensation of $1,554,080.

How old is Mehrdad Mobasher?

Mehrdad Mobasher is 47, he's been the Vice President and Chief Medical Officer of Corvus Pharmaceuticals Inc since 2019. There are 16 older and no younger executives at Corvus Pharmaceuticals Inc. The oldest executive at Corvus Pharmaceuticals Inc is Dr. Richard A. Miller M.D., 70, who is the Co-Founder, Pres, CEO & Chairman.

What's Mehrdad Mobasher's mailing address?

Mehrdad's mailing address filed with the SEC is C/O CORVUS PHARMACEUTICALS, INC., 863 MITTEN ROAD, SUITE 102, BURLINGAME, CA, 94010.

Insiders trading at Corvus Pharmaceuticals Inc

Over the last 9 years, insiders at Corvus Pharmaceuticals Inc have traded over $52,808,904 worth of Corvus Pharmaceuticals Inc stock and bought 11,523,300 units worth $85,214,510 . The most active insiders traders include Holdings A/S Novo, Street Partners Llc Adams, and Capital, Llc Eco R1. On average, Corvus Pharmaceuticals Inc executives and independent directors trade stock every 46 days with the average trade being worth of $1,530,854. The most recent stock trade was executed by William Benton Jones on 6 May 2024, trading 20,000 units of CRVS stock currently worth $34,600.

What does Corvus Pharmaceuticals Inc do?

corvus pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class agents that target the immune system to treat patients with cancer. with accomplished and talented scientists, and top-tier investors, we are well positioned in an exciting new era of immuno-oncology.

Corvus Pharmaceuticals Inc executives and stock owners

Corvus Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Daniel Hunt,
  Senior Vice President, Chief Business Officer
• Mehrdad Mobasher,
  Vice President, Chief Medical Officer
• Richard Miller,
  Chairman of the Board, President, Chief Executive Officer
• Leiv Lea,
  Chief Financial Officer
• Dr. Mehrdad Mobasher M.D., M.P.H.,
  Sr. VP & Chief Medical Officer
• Leiv Lea,
  Chief Financial Officer
• Steve Krognes,
  Independent Director
• Peter Thompson,
  Independent Director
• Elisha Gould,
  Independent Director
• Dr. Richard A. Miller M.D.,
  Co-Founder, Pres, CEO & Chairman
• Scott Morrison,
  Independent Director
• Dr. Peter A. Thompson FACP, M.D.,
  Co-Founder & Independent Director
• Linda Grais,
  Independent Director
• Ian Clark,
  Independent Director
• Edith Mitchell,
  Director
• Erik Verner,
  Vice President of Chemistry Research
• William Jones,
  Senior Vice President of Pharmaceutical Development
• Dr. James T. Rosenbaum M.D.,
  Sr. VP of Research
• Dr. Erik J. Verner Ph.D.,
  Co-Founder
• Stephen Willingham,
  Sr. Scientist
• Alan C. Mendelson Esq.,
  Sec.
• Dr. Long Kwei Ph.D.,
  Sr. VP of Biometrics
• Dr. William Benton Jones,
  Sr. VP of Pharmaceutical Devel.
• Debra Horen SPHR,
  VP of HR
• Street Partners Llc Adams,
  10% owner
• Advisors Llc Orbi Med Capit...,
  
• Jason V Coloma,
  SVP, Chief Business Officer
• Holdings A/S Novo,
  10% owner
• Advisors Llc Orbimed,
  Director
• Terry P Gould,
  
• Joseph J Buggy,
  EVP, Discovery Research
• Advisors Llc Orbi Med Capit...,
  
• Capital, Llc Eco R1,
  10% owner
• Jeffrey Arcara,
  Chief Business Officer